Compare Novo Nordisk A/S (NVO) vs Redwire Corporation (RDW) Price & Performance

Novo Nordisk A/STrade

Redwire CorporationTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Redwire Corporation — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Redwire Corporation trades at $9.7 (market cap $2.05B). The key difference: Novo Nordisk A/S is far larger — about 107.6× Redwire Corporation's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals.

	NVO	RDW
Market Cap	$220.53B	$2.05B
Sector	Health	Technology
52-Week High	$71.70	$25.90
52-Week Low	$35.29	$5.06
Enterprise Value	$239.49B	$2.12B
Dividend Yield	3.63%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.

Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.

Redwire Corporation

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVO

Novo Nordisk sues Eli Lilly over misleading GLP-1 drug ads claiming superior weight-loss results.Proactive Investors · 12 hours agoBearish Novo Nordisk sues Eli Lilly over misleading ads on obesity and diabetes drug efficacy.CNBC · 16 hours agoBearish Novo Nordisk shares jump 27% on strong sales of oral Wegovy and market expansion.Seeking Alpha · 1 day agoBullish View details →

RDW

Redwire gains investor interest with strong backlog and major contracts despite recent revenue missSeeking Alpha · 7 hours agoBullish Redwire shifts to stronger execution with $498M backlog and improved margins, signaling growth potential.Seeking Alpha · 3 days agoBullish View details →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About Redwire Corporation

Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.